In this issue:
Long-term clinical outcomes of AHSCT in MS
Effect of DMTs on disability in RRMS over 15 years
Intrathecal treatment trial of rituximab in progressive MS
Iron heterogeneity in early active MS lesions
Clinical outcomes in RRMS patients who discontinue natalizumab therapy after 2 years
Ublituximab in relapsing forms of MS
Real-world effectiveness of cladribine for Australian patients with MS
Pregnancy outcome following first-trimester exposure to fingolimod
Predictive factors of first line treatment failure in RRMS
Natalizumab vs fingolimod in active relapsing MS
Please login below to download this issue (PDF)